Secondary Osteoporosis
Conditions
Keywords
4 mg zoledronic acid, Colaren, HIV, Secondary Osteoporosis, Man
Brief summary
Clinical trial to assess the effectiveness of the supplement Colaren® associated with zoledronic acid 4mg/annually in the treatment of osteoporosis secondary, compared to standard treatment plus zoledronic acid 4mg/annually. The standard treatment will include 1gr of calcium/day and vitamin D supplement. In both cases, vitamin D levels will be determinated, which should remain at more than 30 ng/mL. Including men with osteoporosis secondary to HIV and men with osteoporosis secondary to any other cause (HIV negative). Vitamin D levels, bone densitometry and markers of metabolism, bone formation and bone resorption will be assessment. The all parameters above will be assessed basally (before the start of treatment), after starting the treatment, an assessment will be made at 12 weeks where vitamin D levels and bone markers will be measured. Meanwhile, at week 24 assess only vitamin D levels; and finally, at week 52 all parameters mentioned above will be measured.
Detailed description
This study is a clinical trial to assess the effectiveness of the supplement Colaren® associated with annually zoledronic acid 4mg, in the treatment of osteoporosis secondary or not to HIV infection, compared to standard treatment plus zoledronic acid 4mg/annually. The standard treatment will include 1gr of calcium/day and vitamin D supplement. In both cases, vitamin D levels will be evaluated, which should remain at more than 30 ng/mL. Including men with osteoporosis secondary to HIV and men with osteoporosis secondary to any other cause (HIV negative). Vitamin D levels, bone densitometry and markers of metabolism, bone formation and bone resorption will be assessment. The all parameters above will be assessed basally (before the start of treatment), after starting the treatment, an assessment will be made at 12 weeks where vitamin D levels and bone markers will be measured. Meanwhile, at week 24 assess only vitamin D levels; and finally, at week 52 all parameters mentioned above will be measured.
Interventions
DRUGColaren in HIV positive
1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
DRUGstandard treatment in HIV positive
2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
DRUGColaren in HIV negative
3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
DRUGstandard treatment in HIV negative
4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
Sponsors
Hospital Civil de Guadalajara
University of Guadalajara
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Study type: Interventional, with four arms: 1. arm: 4 mg zoledronic acid annually plus colaren ® in HIV-positive; 2. arm: 4 mg zoledronic acid annually plus conventional treatment in HIV-positive; 3. arm: 4 mg zoledronic acid annually plus colaren ® in HIV-negative; 4. arm: 4 mg zoledronic acid annually plus conventional treatment in HIV-negative.
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Adult males 18 to 65 years old. * HIV diagnosis (HIV positive group) or negative HIV serology (HIV negative group). * Patients receiving HAART and sustained virologic control for at least two years. * Patients meeting diagnostic criteria for osteoporosis. * Subjects willing to participate voluntarily in this study and give a written consent. * Estimated glomerular filtration rate \>60 mL/min (Using CKD-EPI formula).
Exclusion criteria
* Use of calcium, vitamin D or any other drug with bone activity during the last 90 days previous to the study. * Use of herbs or herb products during the last 90 days previous to the study. * Positive test for HCV or HBV. * Patients who cannot be submitted to complete examination for variable analysis. * Glomerular filtration rate \<60 mL/minute. * Active liver disease. * Non-compliance to treatment (less than 90%). * Patients who are not willing to continue participating. Non-inclusion criteria: * Female patients. * Use of immunosuppressive o immunomodulatory treatment 90 days previous to selection. * Use of prohibited drugs for the study like: antiestrogens, corticosteroids (doses greater than 7.5mg of prednisone/day) 90 days previous to selection. * Use of hormone therapy. * Patients with history or actual use of chemotherapy. * Patients deprived of freedom or imprisoned patients with mental illnesses. * Participant is part of another clinical trial or nutritional program. * Hypogonadism diagnosis with not having received hormonal replacement previous to the study. * Primary osteoporosis diagnosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Bone turnover markers (from baseline to 12 months under treatment) | Time frame: from baseline, 3 and 12 months under treatment. | Plasma measure of (through LEGENDplex (Multiplex)): Bone formation panel that include: Osteoprotegerin (OPG) measure in pg/mL, Alkaline Phosphatase Liver/Bone/Kidney (ALPL) measure in pg/mL, LEPTINA measure in pg/mL and Bone Morphogenetic Protein 2 (BMP-2) measure in pg/mL. Bone resorption panel that include: Osteopontin (OPN) measure in pg/mL, Acid Phosphatase 5 Tartrate Resistant (ACP5) measure in pg/mL, RANKL measure in pg/mL, Tumor Necrosis Factor Alpha (TNF-α) measure in pg/mL, Interleukin 6 (IL-6) measure in pg/mL, Parathyroid Hormone (PTH) measure in pg/mL, Interleukin 1 beta (IL-1β) measure in pg/mL, Dickkopf WNT Signaling Pathway Inhibitor 1 (DKK-1) measure in pg/mL. |
| Change from baseline of Bone mineral density at 12 months | Time frame: from baseline and 12 months under treatment. | Bone mineral density through Dual-energy X-ray absorptiometry (DXA scan) measure. Classification: Normal: T-score ≥ -1.0 Osteopenia: -2.5 \< T-score \< -1.0 Osteoporosis: T-score ≤ -2.5 Severe osteoporosis: T-score ≤ -2.5 with fragility fracture |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tolerability of colaren vs standard treatment (conventional treatment): grading the severity of Adult and Pediatric Adverse Events Version 2.0 | Time frame: evaluate the tolerability from month 1, 3, 6, 9 and 12, under supplementation | Evaluation of tolerability of Colaren and conventional treatment through the Division of AIDS table for grading the severity of Adult and Pediatric Adverse Events Version 2.0, November 2014 Grade 1= Mild Grade 2= Moderate Grade 3= Severe Grade 4= Potentially |
Countries
Mexico
Outcome results
None listed